Pharmaceutical Quality System
- Quality governance and accountability
- Deviation, CAPA and change control
- Quality risk management; document and record control
- Self-inspection, management review and quality metrics

PACKAGE 01
An independent, risk-based review of GMP implementation and inspection preparedness, focused on the evidence that supports routine control and defensible quality decisions.
01 — Service objective
02 — Recommended for
Manufacturers preparing for regulatory inspections
Sites seeking an independent GMP baseline assessment
Facilities facing recurring deviations, CAPA weaknesses or execution inconsistencies
New or expanding operations approaching GMP readiness
03 — Core review scope
04 — Review methodology
Agree facility profile, applicable GMP framework and priority risks
Review selected SOPs, quality records, trends and supporting evidence
Conduct interviews and process walkthroughs (remote or on-site)
Classify findings by compliance significance and product/patient risk
Present priorities, actions and evidence needed for closure
05 — Key deliverables
GMP Gap Assessment Report
Risk-Prioritized Findings Register
Inspection Readiness Summary
Corrective Action Roadmap
Management and Technical Debrief
06 — Delivery model
07 — Indicative duration
08 — Scope boundaries
This is an advisory diagnostic review, not a regulatory certification or guarantee of inspection outcome. CAPA execution, SOP rewriting, validation studies and regulatory representation require separate scope.
AVISAN focused review packages are advisory, risk-based consulting assessments. They do not constitute formal GMP certification, regulatory approval, or a guarantee of inspection outcome.
09 — Request a Technical Review